$7.25
+0.41(6.08%)
Mkt Cap $1.4B
$5.48
$21.31
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Category One Programs (100%).
8-K
Wave Life Sciences announced positive interim Phase 1 data from the INLIGHT trial of WVE-007, showing placebo-adjusted reductions in visceral fat (-14%; p<0.01) and waist circumference (-5.8 cm) at six months after a single 240 mg dose, with muscle preservation. The company plans to initiate the Phase 2a multidose portion in individuals with BMI 35-50 kg/m² in Q2 2026.$1.4B
Market Cap
$45M
Revenue
-$214M
Net Income
Employees287
Fundamentals
How The Business Makes Money
Revenue by Segment
Category One Programs100%($118M)
Activity
What Changed Recently
Company Profile
CIK0001631574
ISINSG9999014716
CUSIPY95308105
Phone65 6236 3388
AddressMarina One East Tower, Singapore, 018936, SG
SEC EDGAR